@SyngeneIntl #Syngene #Q3marketupdates
Q3fy21/20 in mn
Rev 5845 /5191
Ebidta 1933 /1735
PAT 1022 /918

9months fy21 /20
Rev 15257/14046
Ebidta 5026/4749
PAT 2443 /2460
Q3fy20 had exceptional gain of 459 mn leading to higher PAT

Good show
High conviction bet
Doubler for me
#Q3investorpresentations

Collaborated Deerfield discovery & development 3DC to advance integrated drug discovery projects, early target validation to preclinical evaluation

Expanded research facility Genome valley Hyderabad, +90 scientist

Accreditatn NABL fr medical devices
Setup new RT-PCR testing facility approved by NABL & ICMR

360clients
20395 mn Rev Fy20
8 Collaborations with top 10 pharma companies
4200 + scientists
3662 mn PAT fy20
400+ patents ( held with clients )
31541 mn capex Mar 20

Integrated services- drug discovery,development,mfg
Global CRO - Integrated Drug Discovery,Development,Mfg service provider
Small & Large Molecules,ADCs,Oligonucleotides

USFDA,EMA,PMDA approved,GLP Certified,AAALAC Accredited facility

IP assigned to clients
Strong track record of Data Integrity ,Security
Moving from CRO to CRAMS with commercial manufacturing-“Follow the molecule” by expanding into commercialisation

Capacity Expansion - FTE services,mfng, formulation, biologics,stability

Capability Additions- viral testing, Oligonucleotide bioinformatics
New platforms: siRNA,ADC
Small molecules : cGMP facility to mft new chemical entities (NCEs)
Designed to support multigram to 100s of kgs/ batch of Intermediates and APIs for clinical trials
New greenfield investments done in Mangaluru(API plant to gen revs)to support larger commercial scale requirements
Biologics : Mammalian & Microbial capabilities
Can support early stage, late stage and commercial launch supply requirements in mammalian
Capacities to support large volumes for late stage clinical requirements

R&D Expansion: Genome Valley, Hyderabad, commenced operation Aug 19
API Mfg Expansion: Commercial Manufacturing to support product launch in Mangaluru, India -Commenced operation in March 2020; Capacity: 68KL ; Reactor size: 2-12KL

5,000 strong pool of employees
60,000 hrs training per year
4200 scientists
Offering funding for Ph.D. studies of eligible employees
Ph.D. programme launched in partnership with Merck KgaA and Institute of Bioinformatics and AppliedBiotechnology
Ranked as one of the 25 fastest growing companies in India by Outlook Business
India Pharma Award 2019 -For “Excellence in Contract Research and Manufacturing Services” at CPhI & P-MEC India Expo

71% promoter & promoter group holding

Unroll
@threadreaderapp

Compile
@threader_app

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with TheMarket🐝

TheMarket🐝 Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @BullsforBears

22 Jan
#glandpharma
#Q3marketupdates #Q3investorpresentations
Good show inr in mn
Rev 8945 /6712
PAT 2041 /1540
EPS 12.83 /9.95

9 months fy21 /20
Rev 26626 /20909
PAT 7365 /5780
EPS 47.12 / 37.31

Mkt wise
US 6021 /4853
India 1495 /1193
ROW 1078/413 Image
R&D expenses INR Mn
Q3 fy21 434
Q3fy20 312
9M Fy21 916
9m Fy20 749

Net worth INR Mn
Mar 20 36462
Dec 20 56221

Net cash INR Mn
Mar 20 13202
Dec 20 28128

Capital expenditure
9M Fy20 1342
9M Fy21 1826

CFO
9M Fy20 4244
9M fy21 4056 Image
New launches
9months fy21 - 31 product SKUs (4 mols)
US mkt - Dec 20 ,with partners filed 282 ANDAs, 226 approved, 56 pending

Core mkts (US,EU,Canada,Australia)
9M fy21 17415 mn
Growth 20%
Q3 fy21 6021 mn
Growth 24%

Domestic MKT
9M fy2110 product SKUs
Started Remdesivir mftg
Read 10 tweets
22 Jan
@HDFCLIFE #Q3marketupdates #Q3investorpresentations

Mkt share up 214 bps to 16.4%
NBM at 25.6%
8% Individual WRP growth compared to private industry de-growth of 6%
25.6% New Business Margin on the back of growth, balanced product mix Image
17% growth in Protection (Indl) and 42% growth in Annuity in APE terms
22% growth in renewal premium with stable persistency
PAT of Rs 1,042 Cr, with growth of 6%
Solvency healthy at 202% ImageImage
Pvt mkt share rank up to 2,gain 214 bps 14.3 to 16.4%
Balanced product mix %
Savings 35
Non participating savings 30
Ulips 23
Protection 7
Annuity 5

Distribution 300+ partners

AUM 31Dec 20
1.7 lkh cr
Debt:equity mix 64:36
98% debt in Gsecs & AAA

Renewal premium growth 22% Image
Read 9 tweets
20 Jan
#bajajfinance #Q3marketupdates Q3 FY21 highlights
New loans booked 6.04/7.67 mn Q3fy20
Customer franchise Q3fy21 46.31 vs 40.38 mn 31 Q3fy20 Company acquired 2.19 mn new customers in Q3fy21 vs 2.46
mn Q3 FY20.
AUM 31 Dec 20 143,550 cr vs 145,092 crore as of 31Dec 19.
Liquidity surplus Q321 14,347 cr vs 11 ,384 cr Q320 Cost of liquidity surplus for Q3 FY21 was ~ 213 crore vs ~ 83 crore in
Q3 FY20
NII for Q3 FY21 ~ 4,296 vs ~ 4,535 cr Q3 FY20
NII for
Q3 down 239 cr vs Q3 20, due to higher
reversal of interest income & cost of liquidity
PAT Q3 FY21 1146 vs 1614 crore in Q3 FY20
GNPA ,NNPA as of Q3fy20 0.55% & 0.19% vs
1.61% & 0.70% Q3fy20
PCR Q3fy20 65%
Capital adequacy ratio (including Tier-II capital) Q3fy20 28.18%
Read 4 tweets
20 Jan
@ICICILombard
Q3 & 9 months investor presentation

Leading pvt non life insurer since 2004
12 yr GDPI CAGR 12.3%
Mkt share 9 mns 7.2%
Agents 55615
Increasing share tier 3,4 cities
Virtual offices 840
Solvency Dec 20 - 2.76x ( req1.5x)
#Q3marketupdates
#Q3investorpresentations
In rs billion 9 mfy20 /21
Gross written premium 103.6 / 107.6
GDPI 101.32 /105.25
PAT 9.12 /11.27
ROE 21.8 /22.4%
Solvency ratio 2.18 /2.76x
BV 128.76/159.86
EPS 20.07/24.81

Product mix in %
Motor OD & TP 50/49

Motor GDPI Mix
Pvt car 55.9/57.4
2 wheeler 29.6/27.3
CV 14.5/15.3
Advanced premium Dec 31st 20 - 31.97 bn / Sep 20 - 31.6 bn

Health ,travel & PA GDPI Mix 9 mon fy20/21
Individual 22.5 /24.9%
Group others 40 /23.2%
Group employer-employee 37.4 /51.9

Individual health indemnity grew 25.7% for 9 month from 17 at Sep 20
Read 8 tweets
16 Jan
@hcltech
#Q3marketupdates

Fy21 guidance
Revenue expected to grow QoQ betn 2-3% in constant currency for Q4fy21
Ebit exptd to grow betn 21-21.5% for fy21
Rev cross $10bn milestone in Cy20 ,delivering 3.6% yoy growth in constant currency, CY20 delivered Ebidta 26.6%,ebit 21.5%
#hcltech won 13 transformational deals across industry vertical including lifesciences,healthcare ,tech, financial services

Broad based growth driven by Mode 2 & products & platforms
Mode 2 prime driver of growth, up 25% yoy & 10.9% wow in CC,led by traction in cloud& digital
Products & platforms clocked healthy 9.3% yoy growth in CC on strong new license sales & robust renewals
Ebidta at 28.2% expanded 355 bps yoy
Ebit 22.9% expanded 265 bps yoy,129 bps QoQ
Cy20 operating cash flow $2667 mn & FCF $2407 mn ,up 63.5 & 82.8% yoy
Read 4 tweets
16 Jan
@HDFC_Bank #hdfc
#Q3marketupdates
Good show
Standalone profit 8758 cr vs 7416 yoy

NIM up 15.1% 16317 crs vs 14172 yoy

Loan book increased 16% YoY to 10.82 lakh crs & deposits by 19% YoY to 12.71 lakh crs at the end of Dec 20

CASA Dec 20 43% vs 39.5% Dec 19 & 41.6% Sep20
Provisions 3414 cr vs 3703 qoq vs 3043 crs yoy
Gross NPA 8825 crs (0.81 vs 1.08) vs 11305 qoq, down 21.9 % ,down 189 bps
Net NPA 1016 vs 1756 ( 0.09 vs 0.17% ) down 42% qoq ,down 8 bps
Restructuring under Covid 0.5% of advances
5485 vs 5203 branches yoy
15541 vs 14533 ATMs
CAR at 18.9% against regulatory requirement of 11.075%
Total credit cost ratio 1.25% vs 1.41% Q2fy20 vs 1.29% Q3fy20
Balance sheet size 1654226 cr vs 1395336 Q3fy20
Read 7 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!